BURLINGTON, Mass., Nov. 4, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that biosimilar erosion of branded erythropoietin stimulating agent (ESA) market share is likely to be more rapid and more complete in the United States compared to biosimilar erosion seen in Europe since biosimilar ESAs entered the European market in 2007. According to Biosimilars Advisory Service: Physician Perspectives on Erythropoietin Stimulating Agents, Insulin, and Human Growth Hormone, Decision Resources expects the timeline for the uptake of biosimilars among U.S. nephrologists will be fairly aggressive.

More than half of surveyed U.S. physicians anticipate they will begin prescribing a biosimilar ESA within six months of its launch and 88 percent expect to be using biosimilar ESAs within a year. In contrast, the majority of surveyed German nephrologists did not begin using biosimilar ESAs until the drugs had been on the market for 13-24 months. Uptake of biosimilars among surveyed French nephrologists has been even more conservative—60 percent of surveyed physicians report they still do not prescribe biosimilars ESAs.

Decision Resources forecasts that branded ESAs across the seven major pharmaceutical markets (U.S., France, Germany, Italy, Spain, United Kingdom and Japan) will lose $3 billion in combined sales to biosimilar erosion in 2019 alone, and $17.3 billion in combined sales to biosimilar erosion over Decision Resources' 2009-2019 forecast period.

"The global ESA market will be characterized by pricing pressures from a declining market and multiple biosimilar competitors," said Decision Resources Analyst MaryEllen Klusacek, Ph.D. "Biosimilars' lower costs compared with branded biologics will likely be the primary driver of both U.S. and European nephrologists' prescribing of biosimilar ESAs."

The Physician Perspectives on Erythropoietin Stimulating Agents, Insulin, and Human Growth Hormone module of the Biosimilars Advisory Service offers extensive primary research with U.S., French and German nephrologists and endocrinologists to highlight the key expectations that will drive or constrain biosimilar adoption.

Analyst Call

Members of the media are welcome to attend our upcoming analyst call entitled A Forecast of Biosimilars in Nephrology and Endocrinology: How Will Physicians' Perceptions of "Similarity" Affect Prescribing Behavior? This analyst call will be held on Friday, November 12 at 10 a.m. U.S. Eastern Time. For more information, contact Lisa Osgood at losgood@dresources.com.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

Decision Resources

Lisa Osgood

781-993-2606

losgood@dresources.com

Decision Resources, Inc.

Christopher Comfort

781-993-2597

ccomfort@dresources.com

SOURCE Decision Resources

A Majority of Surveyed PCPs and Endocrinologists Indicate that they will Prescribe Contrave, Lorqess and Qnexa if these Therapies are Approved for Obesity

View Now